12/6
08:00 am
tsha
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/15
09:34 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.
11/14
06:30 pm
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
Medium
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
11/14
02:31 am
tsha
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... [Yahoo! Finance]
High
Report
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... [Yahoo! Finance]
11/13
10:50 pm
tsha
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript [Seeking Alpha]
High
Report
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/13
07:22 pm
tsha
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
High
Report
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/13
04:01 pm
tsha
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/12
11:07 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
High
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
11/12
09:03 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
High
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
11/12
08:33 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
High
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
11/6
08:00 am
tsha
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
Medium
Report
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
11/1
04:30 pm
tsha
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/22
08:00 am
tsha
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Medium
Report
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
10/16
03:51 pm
tsha
Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]
Neutral
Report
Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]
10/14
12:57 am
tsha
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data [Seeking Alpha]
Low
Report
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data [Seeking Alpha]
10/4
08:01 am
tsha
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)